NI201800076A - Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen - Google Patents

Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen

Info

Publication number
NI201800076A
NI201800076A NI201800076A NI201800076A NI201800076A NI 201800076 A NI201800076 A NI 201800076A NI 201800076 A NI201800076 A NI 201800076A NI 201800076 A NI201800076 A NI 201800076A NI 201800076 A NI201800076 A NI 201800076A
Authority
NI
Nicaragua
Prior art keywords
contain
preparation
pharmaceutical compositions
ammonium derivatives
new ammonium
Prior art date
Application number
NI201800076A
Other languages
English (en)
Inventor
Paczal Attila
Szlávik Zoltán
Kotschy ANDRÁS
Chanrion Maïa
Leticia Maragno Ana
Geneste Olivier
Demarles Didier
Bálint BALÁZS
Sipos Szabolcs
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of NI201800076A publication Critical patent/NI201800076A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Compuestos de fórmula (I): en la que R1, R2, R3, R4, R5, R6 e Y son como se han definido en la descripción.Medicamentos.
NI201800076A 2016-01-19 2018-07-17 Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen NI201800076A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1650411A FR3046792B1 (fr) 2016-01-19 2016-01-19 Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
NI201800076A true NI201800076A (es) 2018-09-20

Family

ID=55752504

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800076A NI201800076A (es) 2016-01-19 2018-07-17 Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen

Country Status (43)

Country Link
US (1) US10457689B2 (es)
EP (1) EP3405471B1 (es)
JP (1) JP6871275B2 (es)
KR (1) KR20180098677A (es)
CN (1) CN108602841B (es)
AU (1) AU2016387870B2 (es)
BR (1) BR112018014536B1 (es)
CA (1) CA3011761C (es)
CL (1) CL2018001908A1 (es)
CO (1) CO2018007443A2 (es)
CR (1) CR20180363A (es)
CU (1) CU20180073A7 (es)
CY (1) CY1122560T1 (es)
DK (1) DK3405471T3 (es)
EA (1) EA036932B1 (es)
EC (1) ECSP18053634A (es)
ES (1) ES2760545T3 (es)
FR (1) FR3046792B1 (es)
GE (1) GEP20207126B (es)
HR (1) HRP20192073T1 (es)
HU (1) HUE048449T2 (es)
IL (1) IL260550B (es)
LT (1) LT3405471T (es)
MA (1) MA43639B1 (es)
MD (1) MD3405471T2 (es)
ME (1) ME03555B (es)
MX (1) MX2018008808A (es)
MY (1) MY196352A (es)
NI (1) NI201800076A (es)
PE (1) PE20190336A1 (es)
PH (1) PH12018501506A1 (es)
PL (1) PL3405471T3 (es)
PT (1) PT3405471T (es)
RS (1) RS59622B1 (es)
RU (1) RU2743098C2 (es)
SA (1) SA518392049B1 (es)
SG (1) SG11201805913QA (es)
SI (1) SI3405471T1 (es)
SV (1) SV2018005722A (es)
TN (1) TN2018000239A1 (es)
UA (1) UA123508C2 (es)
WO (1) WO2017125224A1 (es)
ZA (1) ZA201804770B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
BR112019013907A2 (pt) * 2017-01-06 2020-02-04 Servier Lab combinação de um inibidor de mcl-1 e um composto de taxano, usos e composições farmacêuticas dos mesmos
CU20190105A7 (es) 2017-06-22 2020-10-20 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico y composiciones farmacéuticas de esta
US10676485B2 (en) 2017-08-15 2020-06-09 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
TW201920204A (zh) * 2017-08-15 2019-06-01 美商艾伯維有限公司 大環mcl-1抑制劑以及使用方法
WO2019035927A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TW202038960A (zh) 2018-11-14 2020-11-01 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
EA202191534A1 (ru) * 2018-12-06 2021-10-27 Ле Лаборатуар Сервье Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
JP2022533400A (ja) 2019-05-20 2022-07-22 ノバルティス アーゲー Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
JP2022551083A (ja) * 2019-10-03 2022-12-07 カリフォルニア インスティチュート オブ テクノロジー Mcl1インヒビター及びその使用
WO2022115451A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
TW202315637A (zh) 2021-06-11 2023-04-16 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
KR20240019330A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항체 약물 접합체의 조합
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
EP0981337A4 (en) * 1997-02-09 2003-03-12 Pharmos Corp IMPROVED ANTI-ANGIOGENIC ACTIVITY OF CONSTANTLY LOADED DERIVATIVES OF STEROID HORMONES
MXPA06015223A (es) * 2004-06-29 2007-11-09 Amgen Inc Furanopirimidinas.
MX2010004260A (es) * 2007-10-16 2010-04-30 Wyeth Llc Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa.
CA2722220C (en) * 2008-04-30 2016-06-07 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
WO2010054285A2 (en) * 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
JP2016504988A (ja) * 2012-11-14 2016-02-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft イミダゾピリジン誘導体
TR201809417T4 (tr) * 2013-05-02 2018-07-23 Hoffmann La Roche Cb2 reseptör agonistleri olarak purin türevleri.
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
BR112018014536A2 (pt) 2018-12-11
ECSP18053634A (es) 2018-07-31
SV2018005722A (es) 2018-10-10
CN108602841B (zh) 2021-03-23
AU2016387870B2 (en) 2021-04-01
EP3405471B1 (en) 2019-10-30
CR20180363A (es) 2018-08-22
MX2018008808A (es) 2018-09-21
JP6871275B2 (ja) 2021-05-12
JP2019511559A (ja) 2019-04-25
BR112018014536B1 (pt) 2022-10-11
FR3046792B1 (fr) 2018-02-02
FR3046792A1 (es) 2017-07-21
HUE048449T2 (hu) 2020-07-28
KR20180098677A (ko) 2018-09-04
HRP20192073T1 (hr) 2020-02-21
TN2018000239A1 (en) 2020-01-16
CY1122560T1 (el) 2021-01-27
SG11201805913QA (en) 2018-08-30
CA3011761C (en) 2020-10-27
ES2760545T3 (es) 2020-05-14
UA123508C2 (uk) 2021-04-14
MA43639B1 (fr) 2020-02-28
SI3405471T1 (sl) 2020-02-28
RU2018129308A3 (es) 2020-02-20
PT3405471T (pt) 2019-12-05
WO2017125224A1 (en) 2017-07-27
CA3011761A1 (en) 2017-07-27
US20190031677A1 (en) 2019-01-31
AU2016387870A1 (en) 2018-07-26
RU2743098C2 (ru) 2021-02-15
RU2018129308A (ru) 2020-02-20
EA201891622A1 (ru) 2019-01-31
US10457689B2 (en) 2019-10-29
EA036932B1 (ru) 2021-01-18
CN108602841A (zh) 2018-09-28
GEP20207126B (en) 2020-06-25
ME03555B (me) 2020-07-20
MY196352A (en) 2023-03-24
CL2018001908A1 (es) 2019-01-04
CO2018007443A2 (es) 2018-07-19
LT3405471T (lt) 2019-12-10
CU20180073A7 (es) 2018-11-06
PE20190336A1 (es) 2019-03-07
IL260550B (en) 2021-06-30
PL3405471T3 (pl) 2020-04-30
SA518392049B1 (ar) 2022-08-04
RS59622B1 (sr) 2020-01-31
DK3405471T3 (da) 2020-01-27
MD3405471T2 (ro) 2020-02-29
EP3405471A1 (en) 2018-11-28
ZA201804770B (en) 2021-08-25
PH12018501506A1 (en) 2019-04-08

Similar Documents

Publication Publication Date Title
NI201800076A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2017003205A1 (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen.
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201800133A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2017005590A (es) Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen
CL2017003163A1 (es) Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201400150A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2021000973A1 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
SV2014004879A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen